Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp. filings document the regulatory record for a genomics diagnostics company focused on pediatric and rare disease testing, including whole exome and genome sequencing. Form 8-K reports include quarterly and annual financial results, earnings presentation exhibits, statement presentation changes, non-GAAP measure methodology, and material financing agreements.
The company's disclosures also cover its capital structure, including Class A common stock and Nasdaq-listed warrants under WGSWW. Proxy materials address executive compensation, equity awards, shareholder voting matters, and other governance items, while debt filings describe term-loan arrangements, guarantor subsidiaries, use of proceeds, repayment obligations, and default provisions.
GeneDx Holdings Corp. reported second quarter 2026 revenue of $114.4 million, up 11% year-over-year, with exome and genome test revenue of $100.3 million, up 17%. Exome and genome volume rose 32% to 30,785 tests, reflecting strong demand across geneticists, pediatric neurology and NICU.
Profitability remained mixed. The company generated adjusted gross margin of about 70% and adjusted net income of $0.4 million, but recorded a GAAP net loss of $17.7 million for the quarter and a net loss of $81.056 million for the first half of 2026. GAAP gross margin was 68%.
Cash, cash equivalents, marketable securities and restricted cash totaled $133.5 million as of June 30, 2026. GeneDx amended and restated its loan agreement with Blackstone, adding a $50.0 million term loan facility that raises total facility capacity to $150.0 million and is paired with a $5.0 million equity investment, resulting in a pro forma cash position of approximately $188 million. Management reaffirmed full-year 2026 guidance, including revenue of $475–$490 million, at least 30% exome and genome volume growth, approximately 70% adjusted gross margin and positive adjusted net income, and guided Q3 2026 revenue to $122–$124 million with adjusted net income of about $2 million.
BlackRock, Inc. filed as a significant shareholder of GeneDx Holdings Corp., reporting beneficial ownership of 1,622,518 shares of Class A stock, representing 5.5% of the class. BlackRock reports sole voting power over 1,588,670 shares and sole dispositive power over 1,622,518 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of GeneDx’s outstanding common shares.
GeneDx Holdings Corp. is having a class of its warrants removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that it has complied with its own rules and the requirements of 17 CFR 240.12d2-2 to strike this warrant class from listing and/or withdraw its registration.
GeneDx Holdings Corp.'s President, Mark A. Gardner, received a grant of 35,441 restricted stock units (RSUs) tied to the company’s Class A common stock. Each RSU converts into one share for no cash payment when it settles, making this a compensation award rather than a market purchase.
The award vests in stages, with 25% of the RSUs vesting each July 1, starting on July 1, 2027, as long as Gardner continues serving the company through each vesting date. After this grant, his reported derivative holdings from this award total 35,441 underlying shares.
GeneDx Holdings Corp. director Jason Ryan reported an equity award vesting and related share movements. He exercised 3,576 restricted stock units into 3,576 shares of Class A common stock at no cost, increasing his direct holdings to 15,480 shares. He also reports indirect ownership of 103,284 shares held by the Jason Ryan 2024 GRAT, where he serves as trustee and sole annuitant. The RSUs represent a right to receive one share each upon settlement, with vesting tied to the 2026 annual shareholder meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings director Joshua Ruch reported equity-based compensation activity and updated holdings in Class A Common Stock. He exercised previously awarded restricted stock units (RSUs) covering 3,576 shares at no cost, increasing his directly held common stock to 33,299 shares.
He also received a new grant of 4,248 RSUs, each representing a right to receive one share of Class A Common Stock for no consideration. This award vests on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service. Entities associated with him hold additional indirect positions in GeneDx shares, for which he may be deemed to share voting and investment discretion, while disclaiming beneficial ownership beyond any pecuniary interest.
GeneDx Holdings Corp. director Richard C. Pfenniger Jr. reported equity compensation changes involving Class A Common Stock and restricted stock units. He exercised 3,576 restricted stock units into the same number of Class A shares, increasing his direct holdings to 45,082 shares after the transaction.
On the same date, he received a new grant of 4,248 restricted stock units, each representing a right to one share of Class A Common Stock for no cash consideration. According to the terms, the new RSU award vests in full on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings Corp. director and 10% owner Keith A. Meister reported equity compensation activity involving Class A Common Stock and restricted stock units. On June 18, 2026, 3,576 RSUs were exercised, converting into 3,576 shares of Class A Common Stock, bringing his direct holdings of this stock to 23,705 shares.
On the same date, he received a new grant of 4,248 restricted stock units, each representing one share of Class A Common Stock upon settlement for no consideration. This award vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. Separate from these grants, investment funds advised by Corvex Management LP hold 333,144 shares, and CMLS Holdings LLC holds 4,784,570 shares, over which Meister shares or may be deemed to share investment discretion.
GeneDx Holdings Corp. director Emily M. Leproust increased her equity stake through routine stock-based compensation. On June 18, 2026, she exercised 3,576 Restricted Stock Units (RSUs), receiving the same number of shares of Class A Common Stock for no cash consideration, bringing her direct holdings to 24,852 shares.
She also received a new grant of 4,248 RSUs, each representing a contingent right to one share of Class A Common Stock upon settlement. According to the award terms, this grant vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to her continued service.